MaxCyte Inc (NASDAQ:MXCT) price on Thursday, April 10, fall -7.51% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.34.
A look at the stock’s price movement, the close in the last trading session was $2.53, moving within a range at $2.215 and $2.53. The beta value (5-Year monthly) was 1.214. Turning to its 52-week performance, $5.26 and $2.25 were the 52-week high and 52-week low respectively. Overall, MXCT moved -26.42% over the past month.
MaxCyte Inc’s market cap currently stands at around $248.10 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-10.
Analysts have a consensus estimate of 9.05M for the company’s revenue for the quarter, with a low and high estimate of 7.78M and 9.9M respectively. The average forecast suggests down to a -20.20% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 41.38M, representing a 7.14% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MXCT is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 1 recommend MXCT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MXCT’s current price about -17.42% and -32.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 29.00, while 7-day volatility ratio is 12.20% and 7.58% in the 30-day chart. Further, MaxCyte Inc (MXCT) has a beta value of 0, and an average true range (ATR) of 0.23. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -156.41% off current price level while to achieve the yearly target high, price needs to move -156.41%. Nonetheless, investors will most likely welcome a -156.41% jump to $6 which is the analysts’ median price.
If we refocus on MaxCyte Inc (NASDAQ:MXCT), historical trading data shows that trading volumes averaged 0.63 over the past 10 days and 633.31K over the past 3 months. The company’s latest data on shares outstanding shows there are 105.71 million shares.
The 7.87% of MaxCyte Inc’s shares are in the hands of company insiders while institutional holders own 71.37% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.98 million on 2025-03-14, giving us a short ratio of 4.12. The data shows that as of 2025-03-14 short interest in MaxCyte Inc (MXCT) stood at 282.99998 of shares outstanding, with shares short rising to 2.77 million registered in 2025-02-14. Current price change has pushed the stock -43.75% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MXCT stock continues to rise going into the next quarter.
